Cocrystal Pharma is a clinical-stage biotechnology company developing small molecule antiviral drugs targeting RNA viruses. Cocrystal has no approved products and no product revenue. Its pipeline covers three active programs: CC-42344, a PB2 inhibitor targeting influenza A designed for oral or inhaled delivery; CDI-988, an oral protease inhibitor targeting both norovirus and coronaviruses; and CC-31244, a NS5B polymerase inhibitor for hepatitis C that completed Phase 2a in 2017 and is now deprioritized pending a development partner. Cocrystal's core differentiator is a structure-based drug design platform developed under Nobel laureate Dr. Roger Kornberg, which uses X-ray crystallography to map viral enzyme structures and design inhibitors targeting conserved regions that the virus cannot mutate without losing function — an approach intended to produce a high barrier to resistance. The company funds operations through equity raises and has only 10 full-time employees, outsourcing clinical, manufacturing, and regulatory work to contract organizations. The long-term business model targets out-licensing candidates to larger pharma in exchange for upfront payments, milestones, and royalties, or advancing candidates through late-stage trials with a strategic partner. Cocrystal's value rests entirely on its pipeline and platform, neither of which has been validated in late-stage trials.